MCI Speech in Noise
Dartmouth-Hitchcock Medical Center · with Dartmouth College · NCT06102486
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 55–80 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 70
- US sites recruiting
- 1
- Study start
- May 18, 2024
- Record last updated
- October 7, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to determine whether people with MCI (Mild Cognitive Impairment) and healthy comparison subjects differ with respect to their ability to hear soft sounds and how their brain understands and processes sound. The investigators are also evaluating, within those with MCI, whether the hearing tests are associated with neurocognitive functioning. The investigators are interested in learning whether changes in cognition in those with MCI can be detected using tests of how the brain processes sound. The investigators hypothesize that participants with MCI will score worse on both hearing tests and neurocognitive tests than participants without MCI. Participants are asked to complete multiple types of hearing tests, take a series of neurocognitive tests, and complete a few questionnaires.
Conditions: Mild Cognitive Impairment
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Adults diagnosed with or suspected to have MCI (for MCI group) or are cognitively normal (for Control group)
- Absence of other risk factors that might affect CAP (Central Auditory Processing) performance (e.g., active ear infections, congenital developmental delay, severe hearing loss)
- Age 55-80
- Normal hearing sensitivity (\<40 dB HL Pure Tone Average (average of 500, 1000, 2000 Hz) thresholds bilaterally
- Normal middle ear function defined by tympanometry (0.3-2.0 ml)
- Native English speaker
Exclusion Criteria
- Active ear infections or abnormal middle ear pathology
- Other health condition prohibiting the completion of the CAP test battery
- Mild to profound peripheral hearing loss (>40 dB (decibel) HL (hearing loss) Pure Tone Average (average of 500, 1000, 2000 Hz) bilaterally
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- History of CNS (Central Nervous System) disorder that might severely impact cognitive function (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, neurosyphilis, intracranial tumors, history of significant head trauma with loss of consciousness (≥30 min), and cerebrovascular disease)
- Severe mental illness (e.g., schizophrenia, bipolar disorder)
- Current, uncontrolled medical condition that could affect cognition (e.g., hypertension)
- History of substance use disorder within the (other than nicotine/caffeine)
- Non-correctable severe hearing or vision loss
- Use of "Cognition Enhancing Drugs"
- Frequent, severe headaches (occasional headaches or migraines are fine)
Recruiting US locations
Space Medicine Lab at Dartmouth-Hitchcock Medical Center
Lebanon, NH 03756
Site contact: Samantha Leigh, BS · 5408195715 · samantha.m.leigh@dartmouth.edu
Study contacts (from the official record)
- Samantha Leigh, BS · 5408195715 · samantha.m.leigh@dartmouth.edu
Similar studies in New Hampshire
All neurology studies in New Hampshire →- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Nashua, NH + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Lebanon, NH + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Nashua, NH + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Kedrion S.p.A.
- Location
- Lebanon, NH + 4 other US sites
- Eligibility basics
- Ages 18+